Клинико-морфологические и молекулярно-генетические предикторы метастатического поражения регионарных лимфатических узлов при раке молочной железы
Аннотация
Несмотря на достаточное количество накопленных данных, все еще не выделены факторы, на основании которых можно было бы с высокой степенью достоверности судить о статусе регионарных лимфатических узлов при раке молочной железы. В обзоре представлены данные литературы, касающиеся влияния клинико-морфологических, молекулярно-биологических и генетических характеристик первичной опухоли на метастатическое поражение регионарных лимфатических узлов. В работу включены данные 66 зарубежных и отечественных статей.
Об авторах
Ю. А. Дергунова
Институт медицины, экологии и физической культуры ФГБОУ ВО «Ульяновский государственный университет»
Россия
Россия
В. В. Родионов
Институт медицины, экологии и физической культуры ФГБОУ ВО «Ульяновский государственный университет»;
ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова» Минздрава России
Россия
Россия
В. К. Боженко
ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова» Минздрава России;
ФГБУ «Российский научный центр рентгенорадиологии» Минздрава России
Россия
Россия
В. В. Кометова
ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова» Минздрава России
Россия
Россия
М. В. Дардык
ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова» Минздрава России
Россия
Россия
Список литературы
1. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2017. 250 с.
2. Petrek J.A., Senie R.T., Peters M., Rosen P.P. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer 2001;92(6):1368–77. PMID: 11745212.
3. Silberman A.W., McVay C., Cohen J.S. et al. Comparative morbidity of axillary lymph node dissectionand the sentinel lymph node technique: Implications for patients with breast cancer. Ann Surg 2004;240(1):1–6. PMID: 15213610.
4. Wilke L.G., McCall L.M., Posther K.E. et al. Surgical complications associated with sentinellymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 2006;13(4):491–500. DOI: 10.1245/ASO.2006.05.013. PMID: 16514477.
5. Mansel R.E., Fallowfield L., Kissin M. et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operablebreast cancer: The ALMANAC Trial. J Natl Cancer Inst 2006;98(9):599–609. DOI: 10.1093/jnci/djj158. PMID: 16670385.
6. Fisher B., Slack N.H., Bross I.D. Cancer of the breast: size of neoplasm and prognosis. Cancer 1969;24(5):1071–80. PMID: 5353940.
7. Chua B., Ung O., Taylor R. et al. Frequency and predictors of axillary lymph node metastases in invasive breast cancer. ANZ J Surg 2001;71(12):723–8. PMID: 11906387.
8. Chen M., Palleschi S., Khoynezhad A. et al. Role of primary breast cancer characteristics in predicting positive sentinel lymph node biopsy results: a multivariate analysis. Arch Surg 2002;137(5):606–9. PMID: 11982477.
9. Harden S.P., Neal A.J., Al Nasiri N. et al. Predicting axillary lymph node metastases in patients with T1 infiltrating ductal carcinoma of the breast. Breast 2001;10(2):155–9. DOI: 10.1054/brst. 2000.0220. PMID: 14965577.
10. Brenin D.R., Manasseh D.M., El-Tamer M. et al. Factors correlating with lymph node metastases in patients with T1 breast cancer. Ann Surg Oncol 2001;8(5):432–7. PMID: 11407518.
11. Vlastos G., Rubio I.T., Mirza N.Q. et al. Impact of multicentricity on clinical outcome in patients with T1–2, N0–1, M0 breast cancer. Ann Surg Oncol 2000;7(8):581–7. PMID: 11005556.
12. Michaelson J.S., Silverstein M., Wyatt J. et al. Predicting the survival of patients with breast carcinoma using tumor size. Cancer 2002;95(4):713–23. DOI: 10.1002/cncr.10742. PMID: 12209713.
13. Viale G., Zurrida S., Maiorano E. et al. Predicting the status of axillarysentinel lymph nodes in 4351 patients with invasive breast carcinomatreated in a single institution. Cancer 2005;103(3):492–500. DOI: 10.1002/cncr.20809. PMID: 15612028.
14. Andea A.A., Bouwman D., Wallis T., Visscher D.W. Correlation of tumor volume and surface area with lymph node status in patients with multifocal/multicentric breast carcinoma. Cancer 2004;100(1):20–7. DOI: 10.1002/cncr.11880. PMID: 14692020.
15. Wiechmann L., Sampson M., Stempel M. et al. Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol 2009;16(10):2705–10. DOI: 10.1245/s10434-009-0606-2. PMID: 19593632.
16. Волченко Н.Н. Морфологические факторы прогноза при раке молочной железы. Российский онкологический журнал 2000;(3):49–53.
17. Chen Z., Yang J., Li S. et al. Invasive lobular carcinoma of the breast: a special histological type compared with invasive ductal carcinoma. PLoS One 2017;12(9). DOI: 10.1371/journal.pone.0182397. PMID: 28863134.
18. Papadatos G., Rangan A.M., Psarianos T. et al. Probability of axillary node involvement in patients with tubular carcinoma of the breast. Br J Surg 2001;88(6):860–4. DOI: 10.1046/j.0007-1323.2001.01779.x. PMID: 11412259.
19. Maibenco D.C., Weiss L.K., Pawlish K.S., Severson R.K. Axillary lymph node metastases associated with small invasive breast carcinomas. Cancer 1999;85(7):1530–6. PMID: 10193943.
20. Winchester D.J., Sahin A.A., Tucker S.L., Singletary S.E. Tubular carcinoma of the breast: predicting axillary nodal metastases and recurrence. Ann Surg 1996;223(3):342–7. PMID: 8604915.
21. Wong S.L., Chao C., Edwards M.J. et al. Frequency of sentinel lymph node metastases in patients with favorable breast cancer histologic subtypes. Am J Surg 2002;184(6):492–8. PMID: 12488144.
22. Wilson A.R.M. Over-diagnosis and breast cancer screening. Eur J Cancer Suppl 2006;4(2):6.
23. Rosen P.P., Wang T.Y. Colloid carcinoma of the breast. Analysis of 64 patients with long term follow up. Am J Clin Pathol 1980;73:304.
24. Rasmussen B.B., Carsten R., Christensen I.B. Prognostic factors in primary mucinous breast carcinoma. Am J Clin Pathol 1987;87(2):155–60. PMID: 3028120.
25. Anan K., Mitsuyama S., Tamae K. et al. Pathological features of mucinous carcinoma of the breast are favourable for breast-conserving therapy. Eur J Surg Oncol 2001;27(5):459–63. DOI: 10.1053/ejso.2001.1142. PMID: 11504516.
26. Pedersen L., Zedeler K., Holck S. et al. Medullary carcinoma of the breast: prevalence and prognostic importance of classical risk factors in breast cancer. Eur J Cancer 1995;31A(13–14):2289–95. PMID: 8652258.
27. Clarijs R., Ruiter D.J., de Waal R.M. Lymphangiogenesis in malignant tumours: does it occur? J Pathol 2001;193(2):143–6. DOI: 10.1002/ path.808. PMID: 11180158.
28. Pathak A.P., Bhujwalla Z.M., Pepper M.S. Visualizing function in the tumorassociated lymphatic system. Lymphat Res Biol 2004;2(4):165–72. DOI: 10.1089/lrb.2004.2.165. PMID: 15650386.
29. Gujam F.J., Going J.J., Edwards J. et al. The role of lymphatic and blood vessel invasion in predicting survival and methods of detection in patients with primary operable breast cancer. Crit Rev Oncol Hematol 2014;89(2):231–41. DOI: 10.1016/j.critrevonc.2013.08.014. PMID: 24075309.
30. Crabb S.J., Cheang M.C., Leung S. et al. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer 2008;8(3):249–56. DOI: 10.3816/CBC.2008.n.028. PMID: 18650155.
31. Klevesath M.B., Pantel K., Agbaje O. et al. Patterns of metastatic spread in early breast cancer. Breast 2013;22(4):449–54. DOI: 10.1016/j.breast.2013.04.017. PMID: 23726130.
32. Zhang S., Zhang D., Yi S. et al. The relationship of lymphatic vessel density, lymphovascular invasion, and lymph node metastasis in breast cancer: a systematic review and meta-analysis. Oncotarget 2017;8(2):2863–73. DOI: 10.18632/oncotarget.13752. PMID: 27926511.
33. Родионов В.В., Панченко С.В., Идрисова С.Р. и др. Номограмма для прогнозирования вероятности метастатического поражения регионарных лимфатических узлов у больных раком молочной железы. Вопросы онкологии 2015;(3):435–8.
34. Rodionov V., Panchenko S., Voronov Y. et al. Predicting axillary metastasis in breast cancer patients without axillary surgery: a new nomogram. Eur J Cancer 2014;50(2):140.
35. Rodionov V., Cometova V., Panchenko S. et al. A new nomogram to predict axillary metastasis in breast cancer patients without axillary surgery. Сancer Res 2015;75(9):1–30.
36. Brenton J.D., Carey L.A., Ahmed A.A., Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005;23(29):7350–60. DOI: 10.1200/JCO.2005.03.3845. PMID: 16145060.
37. Rouzier R., Perou C.M., Symmans W.F. et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11(16):5678–56. DOI: 10.1158/1078-0432.CCR-04-2421. PMID: 16115903.
38. Reis-Filho J.S., Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011;378(9805):1812–23. DOI: 10.1016/S0140-6736(11)61539-0. PMID: 22098854.
39. Dihge L., Bendahl P.O., Ryden L. Nomograms for preoperative prediction of axillary nodal status in breast cancer. Br J Surg 2017;104(11):1494–505. DOI: 10.1002/bjs.10583. PMID: 28718896.
40. Ugras S., Stempel M., Patil S., Morrow M. Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement. Ann Surg Oncol 2014;21(12):3780–86. DOI: 10.1245/s10434-014-3851-y. PMID: 24952028.
41. Jones T., Neboori H., Wu H. et al. Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement? Ann Surg Oncol 2013;20:2866–72.
42. Yu B., Sun X., Shen H.Y. et al. Expression of the apoptosis-related genes BCL-2 and BAD in human breast carcinoma and their associated relationship with chemosensitivity. J Exp Clin Cancer Res 2010;29(1):107. DOI: 10.1186/ 1756-9966-29-107. PMID: 20691103.
43. Santa Cruz Guindalini R., Mathias Machado M.C., Garicochea B. Monitoring survivin expression in cancer: implications for prognosis and therapy. Mol Diagn Ther 2013;17(6):331–42. DOI: 10.1007/s40291-013-0048-1. PMID: 23912862.
44. AI-Joudi F.S., Iskandar Z.A., Hasnan J. et al. Expression of survivin and its clinicopathological correlations in invasive ductal carcinoma of the breast. Singapore Med 2007;48(7):607–14. PMID: 17609820.
45. Adamkov M., Kajo K., Vybohova D. et al. Correlations of survivin expression with clinicomorphological parameters and hormonal receptor status in breast ductal carcinoma. Neoplasma 2012;59(1):30–7. PMID: 22103896.
46. Adamkov М., Vybohova D., Horacekc J. et al. Survivin expression in breast lobular carcinoma: correlations with normal breast tissue and clinicomorphological parameters. Acta Histochemica 2013;115(5):412–7. DOI: 10.1016/j.acthis.2012.10.001. PMID: 23219440.
47. Knauer S.K., Bier C., Schlag P. et al. The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle 2007;6(12):1502–9. PMID: 17582222.
48. Végran F., Boidot R., Bonnetain F. et al. Apoptosis gene signature of survivin and its splice variant expression in breast carcinoma. Endocr Relat Cancer 2011;18(6):783–92. DOI: 10.1530/ERC-11-0105. PMID: 21878572.
49. Athanassiadou A.M., Patsouris E., Tsipis A. et al. The significance of survivin and nectin-4 expression in the prognosis of breast carcinoma. Folia Histochem Cytobiol 2011;49(1):26–33. PMID: 21526486.
50. Span P.N., Tjan-Heijnen V.C., Heuvel J.J. et al. Do the survivin(BIRC5) splice variants modulate or add to the prognostic value of total surviving in breast cancer? Clin Chem 2006;52(9):1693–700. DOI: 10.1373/clinchem.2006.071613. PMID: 16873289.
51. А Luo J., Nikolaev AY., Imai S. et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001;107(2):137–48. PMID: 11672522.
52. Kim H., Lee K.H., Park I.A. et al. Expression of SIRT1 and apoptosis-related proteins is predictive for lymph node metastasis and disease-free survival in luminal A breast cancer. Virchows Arch 2015;467(5):563–70. DOI: 10.1007/s00428-015-1815-7. PMID: 26280894.
53. Bucan V., Mandel K., Bertram C. et al. LEF-1 regulates proliferation and MMP-7 transcription in breast cancer cells. Genes Cells 2012;17(7):559–67. DOI: 10.1111/j.1365-2443.2012.01613. x. PMID: 22686279.
54. Li H., Qiu Z., Li F., Wang C. The relationship between MMP-2 and MMP-9 expression levels with breast cancer incidence and prognosis. Oncol Lett 2017;14(5):5865–70. DOI: 10.3892/ol.2017.6924. PMID: 29113219.
55. Kulic A., Dedic Plavetic N., Vrbanec J., Sirotković-Skerlev M. Low serum MMP-1 in breast cancer: a negative prognostic factor? Biomarkers 2012;17(5):416–21. DOI: 10.3109/1354750X.2012.678885. PMID: 22515421.
56. Song N., Sung H., Choi J.Y. et al. Preoperative serum levels of matrix metalloproteinase-2(MMP-2) and survival of breast cancer among Korean women. Cancer Epidemiol Biomarkers Prev 2012;21(8):1371–80. DOI: 10.1158/1055-9965.EPI-12-0293. PMID: 22634108.
57. Sung H., Choi J.Y., Lee S.A. et al. The association between the preoperative serum levels of lipocalin-2 and matrix metalloproteinase-9 (MMP-9) and prognosis of breast cancer. BMC Cancer 2012;12:193. DOI: 10.1186/1471-2407-12-193. PMID: 22640376.
58. Wan H., Du Z., Long Q. et al. Criteria derived from serum markers can precisely evaluate axillary status in breast cancer patients. J Surg Res 2017;208:211–8. DOI: 10.1016/j.jss.2016.08.086. PMID: 27993212.
59. Suzuki T., Urano T., Miki Y. et al. Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. Cancer Sci 2007;98(5):644–51. DOI: 10.1111/j.1349-7006.2007.00444.x. PMID: 17359284.
60. Sorlie T., Perou C.M., Tibshirani R. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98(19):10869–74. DOI: 10.1073/pnas.191367098. PMID: 11553815.
61. Hurtado A., Holmes K.A., Ross-Innes C.S. et al. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 2011;43(1):27–33. DOI: 10.1038/ng.730. PMID: 21151129.
62. Badve S., Nakshatri H. Oestrogenreceptor-positive breast cancer: towards bridging histopathological and molecular classifications. J Clin Pathol 2009;62(1): 6–12. DOI: 10.1136/jcp.2008.059899. PMID: 18794199.
63. Mehra R., Varambally S., Ding L. et al. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res 2005;65(24):11259–64. DOI: 10.1158/0008-5472.CAN-05-2495. PMID: 16357129.
64. Mehra R.J., Jain R.K., Leung S. et al. FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Res Treat 2012;131(3):881–90. DOI: 10.1007/s10549-011-1482-6. PMID: 21503684.
65. Hisamatsu Y., Tokunaga E., Yamashita N. et al. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer. Breast Cancer 2015;22(5):520–8. DOI: 10.1007/s12282-013-0515-x. PMID: 24415069.
66. Gyorffy B., Hatzis C., Sanft T. et al. Multigene prognostic tests in breast cancer: past, present, future. Breast Cancer Res 2015;17:11. DOI: 10.1186/s13058-015-0514-2. PMID: 25848861.
Для цитирования:
Дергунова Ю.А., Родионов В.В., Боженко В.К., Кометова В.В., Дардык М.В. Клинико-морфологические и молекулярно-генетические предикторы метастатического поражения регионарных лимфатических узлов при раке молочной железы. Успехи молекулярной онкологии. 2018;5(3):8-16. https://doi.org/10.17650/2313-805X-2018-5-3-8-16
For citation:
Dergunova Y.A., Podionov V.V., Bozhenko V.K., Kometova V.V., Dardyk M.V. Clinical, morphological, and molecular genetic predictors of metastatic lesions in the regional lymph nodes in breast cancer. Advances in Molecular Oncology. 2018;5(3):8-16. (In Russ.) https://doi.org/10.17650/2313-805X-2018-5-3-8-16
Просмотров: 209
Послать статью по эл. почте 